Alumis Inc. (ALMS) entered a merger agreement on February 6, 2025, to acquire Acelyrin, Inc. (SLRN) in an all-stock deal.
Under the agreement, Acelyrin stockholders will receive 0.4274 shares of Alumis common stock for each share of Acelyrin common stock owned. The deal is valued at $2.82 per share, representing a 48.42% premium from the stock’s last close.